Brokers Offer Predictions for Aratana Therapeutics Inc.’s Q3 2016 Earnings (PETX)
Aratana Therapeutics Inc. (NASDAQ:PETX) – William Blair lowered their Q3 2016 earnings per share estimates for Aratana Therapeutics in a research note issued on Thursday. William Blair analyst J. Kreger now expects that the brokerage will earn ($0.48) per share for the quarter, down from their previous estimate of ($0.47). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Aratana Therapeutics’ Q4 2016 earnings at ($0.38) EPS, FY2016 earnings at ($0.77) EPS, FY2017 earnings at ($1.14) EPS, FY2018 earnings at ($0.35) EPS, FY2019 earnings at $0.34 EPS and FY2020 earnings at $1.11 EPS.
Several other equities analysts have also recently issued reports on the company. Lake Street Capital reissued a “buy” rating and set a $15.00 target price on shares of Aratana Therapeutics in a research note on Tuesday, September 6th. Jefferies Group began coverage on Aratana Therapeutics in a research note on Friday, August 19th. They set a “buy” rating and a $13.00 target price on the stock. Barclays PLC reduced their target price on Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating on the stock in a research note on Thursday, August 11th. Credit Suisse Group AG reissued a “buy” rating and set a $11.00 target price on shares of Aratana Therapeutics in a research note on Wednesday, August 10th. Finally, Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $11.28.
Aratana Therapeutics (NASDAQ:PETX) opened at 9.36 on Monday. The firm’s 50-day moving average price is $9.27 and its 200 day moving average price is $7.35. The company’s market capitalization is $331.48 million. Aratana Therapeutics has a 52 week low of $2.56 and a 52 week high of $10.73.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/brokers-offer-predictions-for-aratana-therapeutics-inc-s-q3-2016-earnings-petx.html
Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.37. Aratana Therapeutics had a negative return on equity of 17.53% and a negative net margin of 166.67%. The business had revenue of $38.05 million for the quarter, compared to analysts’ expectations of $15.14 million. During the same period last year, the business earned ($0.23) EPS.
Several large investors have recently added to or reduced their stakes in PETX. Franklin Resources Inc. boosted its stake in Aratana Therapeutics by 23.7% in the first quarter. Franklin Resources Inc. now owns 5,421,549 shares of the biopharmaceutical company’s stock worth $29,927,000 after buying an additional 1,037,646 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Aratana Therapeutics by 8.1% in the second quarter. BlackRock Fund Advisors now owns 1,308,679 shares of the biopharmaceutical company’s stock worth $8,271,000 after buying an additional 98,007 shares in the last quarter. Vanguard Group Inc. boosted its stake in Aratana Therapeutics by 20.4% in the second quarter. Vanguard Group Inc. now owns 1,270,655 shares of the biopharmaceutical company’s stock worth $8,031,000 after buying an additional 214,900 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Aratana Therapeutics by 5.1% in the second quarter. Massachusetts Financial Services Co. MA now owns 971,935 shares of the biopharmaceutical company’s stock worth $6,143,000 after buying an additional 47,102 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in Aratana Therapeutics by 14.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 869,516 shares of the biopharmaceutical company’s stock worth $5,495,000 after buying an additional 109,243 shares in the last quarter. 85.56% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider Ernst Heinen sold 10,000 shares of the stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $10.00, for a total value of $100,000.00. Following the sale, the insider now directly owns 115,494 shares of the company’s stock, valued at $1,154,940. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Craig A. Tooman sold 30,000 shares of the stock in a transaction on Friday, September 9th. The stock was sold at an average price of $9.25, for a total value of $277,500.00. Following the completion of the sale, the insider now directly owns 72,424 shares in the company, valued at $669,922. The disclosure for this sale can be found here. 6.70% of the stock is owned by insiders.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.